

# Chronic obstructive pulmonary disease (COPD) as syndrome of accelerated aging

<b>Submission date</b> 15/03/2010	<b>Recruitment status</b> No longer recruiting	<input checked="" type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 18/05/2010	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 18/05/2010	<b>Condition category</b> Respiratory	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

**Plain English summary of protocol**  
Not provided at time of registration

## Contact information

**Type(s)**  
Scientific

**Contact name**  
Dr Erica Rutten

**Contact details**  
Centre for Integrated Rehabilitation of Organ Failure (CIRO)  
P.O. Box 4080  
Horn  
Netherlands  
6080 AB  
ericarutten@ciro-horn.nl

## Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

**Secondary identifying numbers**  
3.2.09.049

## Study information

**Scientific Title**

Systemic manifestation and co-morbidity in chronic obstructive pulmonary disease (COPD) are associated with circulating markers of aging: a cross-sectional observational study with a longitudinal follow-up for two years

**Acronym**

AGOPD

**Study objectives**

We hypothesise that accelerated aging is a key pathophysiological mechanism of chronic obstructive pulmonary disease (COPD), and that aging markers are related to important domains of the disease, particularly to the systemic phenotype of COPD and the clinically manifested co-morbidity.

**Ethics approval required**

Old ethics approval format

**Ethics approval(s)**

Maastricht Medical Ethical Commission, pending as of 16/03/2010

**Study design**

Cross-sectional observational study with a longitudinal follow-up

**Primary study design**

Observational

**Secondary study design**

Cross-section survey

**Study setting(s)**

Hospital

**Study type(s)**

Diagnostic

**Participant information sheet**

Not available in web format, please use the contact details below to request a patient information sheet

**Health condition(s) or problem(s) studied**

Chronic obstructive pulmonary disease (COPD)

**Interventions**

At baseline and 2 years later, the participants will be invited for two test days; one day at the Center of Expertise for Chronic Organ Failure (CIRO), Horn, and one day at the Maastricht University Medical Center (MUMC).

For COPD patients, the test days will be planned before the start of the rehabilitation. The first day and after overnight fast, venous blood of about 30 ml venous blood in total will be collected, an amount which is not of clinical relevance, but the venepuncture can cause a blue spot. The electrocardiography and the pulse wave velocity will also be performed in the fasted state.

During this procedure, the arm will be occluded for 5 minutes. This may give a tingling feeling, but this feeling disappears when the occlusion is removed. Dual x-ray absorptiometry scan will be performed after emptying the bladder and a lung function measurement will take place after consuming breakfast. On the second day at the MUMC, all subjects will be invited for a high resolution computed tomography (HRCT) scan of the thorax.

During the follow-up of 2 years, medical status of the participants will be followed by a telephone contact every three months. For the COPD patients, lung function measurement and dual energy x-ray absorptiometry (DEXA) scan will be performed during the assessment of the rehabilitation at baseline. These tests do not have to be repeated. In a subgroup of 25 patients with the emphysema like phenotype, 25 patients with the non-emphysema like phenotype and 50 smoking healthy controls, circulating concentration of hepatokines and deoxyribonucleic acid (DNA) repair mechanism will be detected in a second venous blood sample during the second test day.

### **Intervention Type**

Other

### **Phase**

Not Applicable

### **Primary outcome measure**

All analysed at baseline:

1. Markers of aging
2. Objective diagnosed co-morbidity
3. Circulating hepatokines

### **Secondary outcome measures**

All analysed at baseline:

1. Markers of systemic inflammation and oxidative stress
2. Classic characterisation of COPD

### **Overall study start date**

01/10/2010

### **Completion date**

01/10/2014

## **Eligibility**

### **Key inclusion criteria**

COPD patients:

1. Diagnosis of COPD according to the American Thoracic Society (ATS) Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines (forced expiratory volume in one second [FEV1] less than 80% predicted and FEV1/forced vital capacity [FVC] less than 70% and less than 10% predicted improvement in FEV1 after  $\beta_2$ -agonist inhalation
2. Both male and female, aged from 50 to 75 years
3. No respiratory tract infection or exacerbation of the disease for less than 4 weeks before the study
4. Capable of providing informed consent

Healthy subjects:

1. Healthy subjects as judged by a physician
2. Without diagnosed COPD or any other described co-morbidity/chronic disease
3. Both male and female, aged from 50 to 75 years

**Participant type(s)**

Patient

**Age group**

Adult

**Sex**

Both

**Target number of participants**

600

**Key exclusion criteria**

COPD patients:

1. Any kind of carcinogenic pathology less than 5 years before study participation
2. Participation in any other studies involving investigational or marketed products concomitantly or less than 4 weeks prior to entry into the study

Healthy subjects:

1. Investigator's uncertainty about the willingness or ability of the subject to comply with the protocol requirements
2. Participation in any other study involving investigational or marketed products concomitantly or within two weeks prior to entry into the study

**Date of first enrolment**

01/10/2010

**Date of final enrolment**

01/10/2014

**Locations**

**Countries of recruitment**

Netherlands

**Study participating centre**

Centre for Integrated Rehabilitation of Organ Failure (CIRO)

Horn

Netherlands

6080 AB

**Sponsor information**

**Organisation**

Dutch Asthma Foundation (Netherlands)

**Sponsor details**

P.O.Box 5  
Leusden  
Netherlands  
3830 AA

**Sponsor type**

Research organisation

**Website**

<http://www.astmafonds.nl>

**ROR**

<https://ror.org/00ddgbf74>

**Funder(s)****Funder type**

Research organisation

**Funder Name**

Dutch Asthma Foundation (Netherlands)

**Results and Publications****Publication and dissemination plan**

Not provided at time of registration

**Intention to publish date****Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Not provided at time of registration